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Abstract
Background: Previous studies of magnetic resonance imaging (MRI) as a diagnostic tool for central nervous
system (CNS) syndromes in systemic lupus erythematosus (SLE) contained several limitations such as study design,
number of enrolled patients, and definition of CNS syndromes. We overcame these problems and statistically
evaluated the diagnostic values of abnormal MRI signals and their chronological changes in CNS syndromes of SLE.
Methods: We prospectively studied 191 patients with SLE, comparing those with (n = 57) and without (n = 134)
CNS syndrome. CNS syndromes were characterized using the American College of Rheumatology case definitions.
Results: Any abnormal MRI signals were more frequently observed in subjects in the CNS group (n = 25) than in
the non-CNS group (n = 32) [relative risk (RR), 1.7; 95% confidence interval (CI), 1.1-2.7; p = 0.016] and the positive
and negative predictive values for the diagnosis of CNS syndrome were 42% and 76%, respectively. Large
abnormal MRI signals (ø ≥ 10 mm) were seen only in the CNS group (n = 7; RR, 3.7; CI, 2.9-4.7; p = 0.0002),
whereas small abnormal MRI signals (ø < 10 mm) were seen in both groups with no statistical difference. Large
signals always paralleled clinical outcome (p = 0.029), whereas small signals did not (p = 1.000).
Conclusions: Abnormal MRI signals, which showed statistical associations with CNS syndrome, had insufficient
diagnostic values. A large MRI signal was, however, useful as a diagnostic and surrogate marker for CNS syndrome
of SLE, although it was less common.
Background
Central nervous system (CNS) lupus is a serious and
potentially life-threatening manifestation of systemic
lupus erythematosus (SLE), occurring in 37-95% of
cases, and is associated with an increased risk of death
[1]. Despite its frequency and severity, the lack of a
diagnostic gold standard makes it challenging to differ-
entiate primary CNS lupus from secondary neuropsy-
chiatric (NP) manifestations unrelated to SLE at their
onsets [1-3]. The American College of Rheumatology
(ACR) has developed a standardized nomenclature sys-
tem that provides case definitions for 19 NP syndromes
associated with SLE, including reporting standards and
recommendations for laboratory and imaging tests [2].
Although this standardized nomenclature has helped to
clarify a complicated situation, its usefulness as a clinical
diagnostic criterion remains to be determined.
While neurological or psychological examinations are
still the cornerstones for the diagnosis of CNS lupus,
neuroimaging, electroencephalography and cerebrospinal
fluid tests are also used [1,2,4-8]. Among conventional
and more recent neuroimaging tools, conventional mag-
netic resonance imaging (MRI) still remains the modal-
ity of choice because of its availability and accessibility.
Newer tools, such as magnetic resonance spectroscopy
(MRS), magnetization transfer imaging (MTI), diffusion
weighted imaging (DWI), perfusion weighted imaging
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(SPECT), and positron emission tomography (PET) are
still investigational (SPECT has probably been most
established among these), although they have provided
data to greatly improve our understanding of CNS lupus
[4-7]. However, even the diagnostic validity and useful-
ness of conventional MRI is not yet fully established,
because most published studies are small in size (n <
100, mostly < 50), retrospective, or based on non-stan-
dardized case definitions and some include only NPSLE,
not SLE patients without CNS syndromes [2,4-7,9]. In
order to overcome these problems of the previous stu-
dies we prospectively enrolled the largest number of
SLE patients with or without active CNS syndrome
which was categorized based on the ACR standardized
case definitions and evaluated the accuracy and useful-
ness of conventional MRI in the diagnosis of CNS syn-
drome. We also assessed the suitability of conventional
MRI as a surrogate marker for CNS lupus.
Methods
Patient population
This was a prospective study of 191 SLE patients with
or without NP syndromes who were admitted to the
Aoyama Hospital of The Tokyo Women’s Medical Uni-
versity from August 1994 through October 2003. All
these patients had 4 or more revised ACR (formerly, the
American Rheumatism Association) criteria for SLE
[10]. At our institution, those patients suspected of or
newly diagnosed as having SLE were typically admitted
for systemic evaluation regardless of the severity of the
disease, and were eligible for inclusion in the study. Pre-
viously diagnosed SLE patients whose disease (NP syn-
drome or other manifestations of SLE) flared were also
enrolled in the study. A total of 269 patients with SLE
gave informed consent for inclusion in this study,
including their MRI examinations during the above per-
iod. Among these 269 patients, those who had non-SLE-
related NP manifestations arising from infection, uremia,
electrolyte imbalance, hypoxia, brain tumor, trauma, pri-
mary mental disease or drug use (n = 45) or past his-
tories of NP involvement (n = 33) were excluded prior
to MRI scans. The patients were excluded because we
wanted to compare recently (i.e. within a month) diag-
nosed active CNS lupus patients to non-NPSLE patients
and because the unrelated conditions could affect cur-
rent symptoms or laboratory and MRI findings. At the
time of admission to the hospital, each patient com-
pleted a standardized medical history, including medica-
tion use, and had physical examinations that included
neurologic and rheumatologic examinations. Psychiatric
examinations were employed when indicated. Serology
profiling for each patient was performed using standard
immunoassays. The activity of SLE was measured using
the SLE Activity Index (SLEDAI) [11]. Treatment with
corticosteroids or immunosuppressive drugs was insti-
tuted as indicated following completion of these evalua-
tions. One non-NPSLE patient at admission, who later
developed NPSLE, was reevaluated at the onset of the
NP syndrome (a mood disorder in this patient) and was
reclassified into the CNS group. In this patient, data
from the reevaluation, including the results of MRI,
were used. Subjects were classified into the CNS group
or the non-CNS group according to the presence or
absence of active CNS syndromes. The CNS group was
then further classified into t h en e u r o l o g i cd i s o r d e r s
group consisting of patients with neurologic disorders
with or without other NP syndromes, or the psychiatric
disorders group comprising patients with psychiatric dis-
orders with or without other NP syndromes [2,4,8,12].
Thirteen patients were classified into both neurologic
and psychiatric disorders groups. Detailed diagnostic cri-
teria for these groups are described below. The study
was approved by the Ethical Committee of our institu-
tion and the Helsinki declaration was followed through-
out the study.
Diagnosis of CNS lupus
Although ACR nomenclature and case definitions
include 12 CNS syndromes and 7 peripheral nervous
system syndromes [2,4,8,12], we included only the 12
CNS syndromes in the present study because of the sub-
stantial differences in anatomy, function, and clinical
characteristics between the central and peripheral ner-
vous systems. Slight or mild cognitive dysfunction with-
out significant clinical impairment, as revealed by the
detailed neuropsychological tests described below in
“Evaluation of psychological impairment,” was excluded
from the CNS syndromes in our study. Using published
normative data, patients in this category (n = 3) exhib-
ited less than the median of normal controls by 2 stan-
dard deviation (SD) in 2 or more of areas of cognitive
function without significant clinical impairment [13].
Tension headache, or episodic tension type headache,
was also excluded from our study.
The final clinical diagnosis and classification of the
various NP syndromes for inclusion in the study were
made by an experienced rheumatologist (M. Hara) and
psychiatrist (K. N.), according to the standardized ACR
nomenclature and case definitions for neuropsychiatric
lupus syndromes [2]. These decisions were based on the
medical history and neuropsychological examinations by
rheumatologists, an experienced neurologist (S. U.) and
a psychiatrist (K. N.) and supported by conventional
laboratory tests and appropriate complementary tests,
including MRI, electroencephalography, and cerebral
spinal fluid tests, and the clinical course. Cases before
the ACR nomenclature and case definitions for NPSLE
were published in 1999 were originally diagnosed and
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nosed retrospectively according to the ACR criteria.
Clinical improvement of CNS lupus was defined as
either sustained complete recovery or recovery with
minor residual deficits that no longer required hospitali-
zation. Stabilization was defined as the status in which
no new clinical (i.e., neurologic or psychiatric) abnorm-
alities occurred, although the previous abnormalities
remained. Deterioration was defined as the status in
which previous neuropsychiatric symptoms were exacer-
bated or new ones developed during follow-up [14,15].
Evaluation of psychological impairment
Cognitive function was evaluated using the Mini Mental
Status Examination [16] and the ACR-suggested test
battery [2], including the WAIS-R/Digit Span (Forward)
[17], Trail Making Test (Pa r tB )[ 1 8 ] ,W A I S - R / D i g i t
Span (Backward) [17], Wisconsin Card Sorting Test
[18], Rey Auditory-Verbal Learning Test [17], WAIS-R/
Block Design [17], Animal Naming Test [18], WAIS-R/
Similarities [17], Trail Making Test (Part A) [18], and
WAIS-R/Digit Symbol Substitution Test [17]. Mood and
behavioral dysfunction was assessed by clinical observa-
tion, patient history and standardized instruments, such
as the Profile of Mood States [19]. However, these for-
mal neuropsychological tests were not performed routi-
nely in all patients and the diagnosis of cognitive, mood,
or behavioral dysfunction was on the basis of clinical
assessment using the ACR definitions [2], rather than
formal neuropsychological testing, especially in cases
where disturbance of consciousness, such as acute con-
fusional state, created difficulty in taking the tests. The
impact of disturbance on daily life and prior occupa-
tional and social functioning was determined from infor-
mation provided by the patient or other informants.
Magnetic resonance imaging (MRI)
MRI was performed using a 1.5T MR scanner (Toshiba
Medical Systems, Otawara, Tochigi, Japan) within a
week from admission and within a month from onset of
NP symptoms in the CNS group. Scans were aligned
parallel to the axial plane through the anterior to pos-
terior commissure and covered the entire brain in all
sequences. T1-weighted, T2-weighted, and fluid-attenu-
ated inversion recovery (FLAIR) images were acquired
from all patients who had brain MRIs. The software, but
not the hardware of the MR scanner was updated once
in 2000, which improved its resolution but did not prac-
tically influence the sensitivity of this study. The MRIs
were interpreted at the time of scanning by an experi-
enced radiologist (T. Y.) who was not blinded to all the
clinical and sequential information. MRI tests were
defined as ‘positive’ when any abnormal intensity lesion
was found. The abnormal MRI signals were classified
into large abnormal MRI signals (ø ≥ 10 mm) or small
abnormal MRI signals (ø < 10 mm) [15]. Mild brain
atrophy, characterized by loss of brain volume, was not
included among MRI abnormalities in the present study
because it is not a well-established abnormality [6], even
though it is the most frequent abnormal findings in SLE
[9]. Moderate to severe brain atrophy was not seen at
the time of enrolment in the study population. CNS
lupus patients who had had abnormalities in initial
MRIs were reevaluated by MRI at approximately 1 year
or when clinical amelioration or deterioration was deter-
mined. MRI improvement was defined as a more than
50% decrease in the number or size of abnormal MRI
signals. MRI stabilization was defined as occurring when
no new abnormalities were detected, but previously
detected abnormalities were unchanged or only slightly
changed. Deterioration was defined as when the pre-
viously detected abnormalities became exacerbated or
new ones developed during follow-up [15].
Statistical analyses
Diagnostic tests evaluated in the present study were cor-
related with the final clinical diagnosis for each. Two-
group comparisons were analyzed using the Mann-
Whitney U test for continuous variables and Fisher’s
exact test for categorical variables. Values of p <0 . 0 5
were considered statistically significant. Accuracy, posi-
tive predictive value (PPV), and negative predictive value
(NPV) of MRI and the relative risk of CNS lupus to
MRI were also calculated. All statistical analyses were
performed using SPSS statistical software (version 14.0J;
SPSS Inc., Tokyo, Japan).
Results
Clinical characteristics of the patients
Of the 191 patients with SLE enrolled in the present
study, 176 were women and 15 were men. The median
age of the patients was 32 years (range; 11 to 68 years).
The median disease duration since the diagnosis of SLE
was 1 year (range; 0 to 22 years). The patients were all
Japanese, except for 1 woman who was Chinese. Current
CNS syndromes were observed in 57 patients (CNS
group), while the remaining 134 patients did not have
either current CNS syndromes or a history of CNS syn-
dromes (non-CNS group). Detailed clinical characteris-
tics of the study patients are summarized in Table 1.
Arthritis was significantly more frequent in the non-
CNS group (p = 0.036) and levels of serum anti-dsDNA
antibody were also significantly higher in the non-CNS
group (p = 0.035). Although the SLEDAI score differed
significantly between the 2 groups (p < 0.0001), the
“SLEDAI score without CNS syndrome,” determined by
evaluating and summing the clinical variables of the
SLEDAI score other than CNS syndrome for each
patient, was not (Table 1).
Table 2 shows the distribution of types of CNS syn-
drome in the study group. Neurologic disorders alone
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alone in 36, and both in 13. CNS syndromes in patients
with both disorders were seizure disorders (n = 7),
demyelinating syndrome (n = 4), aseptic meningitis (n =
2), acute confusional state (n = 11), anxiety disorder (n
= 1) and psychosis (n = 1). The most frequent manifes-
tation of neurologic disorders was seizures and seizure
disorders (n = 18), while that of psychiatric disorders
was acute confusional state (n = 24).
Initial MRI
All patients enrolled in the present study underwent
brain MRI. We assessed the diagnostic value of brain
MRI for CNS lupus using this data. Abnormal MRI sig-
nals were more frequently observed in the CNS group
(n = 25, 44%) than in the non-CNS group (n = 32, 25%)
with significant statistical differences [relative risk (RR),
1.7; 95% confidence interval (CI), 1.1-2.7; p =0 . 0 1 6 ]
(Table 3). This resulted in a diagnostic accuracy of 65%,
a PPV of 42% and a NPV of 76% for MRI use in diagno-
sis of CNS lupus. Significant differences were also found
when the CNS group with neurologic disorders (n = 17;
RR, 2.3; CI, 1.3-4.1; p = 0.007) and the CNS group with
psychiatric disorders (n = 16; RR, 1.9; CI, 1.1-3.4; p =
0.038) were separately compared with the non-CNS
group.
Because the predictive values, in particular the PPV, of
MRI were not considered adequate for the practical
diagnosis of CNS lupus, we then analyzed the compara-
tive sizes of abnormal MRI signals. Abnormal MRI sig-
nals on T2-weighted or FLAIR images of the brains of
SLE patients were usually small nonspecific fixed foci of
increased signal in deep white matter (Figure 1A). Mid-
to large-sized high intensity lesions in brain T2-
weighted or FLAIR images were occasionally observed,
but only in the CNS group (Figure 1B). When abnormal
signals in MRI were classified by size, large signals (ø ≥
10 mm) were seen only in the CNS group (n = 7; 12%;
RR, 3.7; CI, 2.9-4.7; p = 0.0002) (Table 4). Smaller sig-
nals (ø < 10 mm; mostly ø < 5 mm) were seen in both
the CNS and non-CNS groups with no significant differ-
ence (n = 18; 32% and 34; 25%, respectively; RR, 1.2; CI,
0.8-2.0; p = 0.380) (Table 4). Calculations showed 74%
accuracy, a PPV of 100% and an NPV of 73% using
large abnormal MRI signals for the diagnosis of CNS
lupus. Clinical syndromes of the patients showing large
abnormal MRI signals included seizure disorders (n =
2), cerebrovascular disease (n = 1), demyelinating syn-
drome (n = 3), and acute confusional state (n = 5)
(Table 5).
Chronological changes in abnormal MRI signals
The association between chronological changes of
abnormal MRI signals and the clinical outcome in the
CNS group was examined. As shown in Tables 5 and 6,
large signals always decreased in size or resolved
Table 1 Characteristics of the 191 patients with SLE
CNS Group Non-CNS Group p†
Characteristics n = 57 n = 134
Female/male 53/4 123/11 1.000
Age at evaluation (yrs) 28 : [23, 43] 34 : [25, 45] 0.160
SLE duration at evaluation (yrs) 1 : [0, 5] 1 : [0, 4] 0.322
Clinical features
Malar rash/discoid rash 25 (44%) 42 (31%) 0.101
Oral or nasal ulcers 1 (2%) 13 (10%) 0.068
Arthritis 16 (28%) 60 (45%) 0.036
Serositis 7 (12%) 18 (13%) 1.000
Renal disorder 19 (33%) 37 (28%) 0.488
Vasculitis 1 (2%) 7 (5%) 0.439
Antinuclear antibody 52 (95%) 131 (98%) 0.150
Antiphospholipid antibodies‡ 13 (23%) 39 (29%) 0.478
Lymphocytopenia (< 1500/mm
3) 44 (80%) 91 (69%) 0.154
SLEDAI 15 : [10, 22] 9 : [5, 11] < 0.0001
SLEDAI without CNS score 11 : [7, 16] 9 : [5, 11] 0.606
Anti-dsDNA antibody (RIA; IU/ml) 8 : [3, 37] 20 : [5, 98] 0.035
CH50 (U/ml) 33.2 : [21.2, 39.2] 29.8 : [20.4, 38.3] 0.496
*Except where indicated otherwise, values of continuous data are the median : [25% percentile, 75% percentile].
†P values were determined by Fisher’s exact test or Mann-Whitney U test.
‡Antiphospholipid antibodies include lupus anticoagulant, anti-cardiolipin antibodies, and anti-b2GPI antibodies.
CNS: central nervous system; SLEDAI: systemic lupus erythematosus disease activity index; RIA: radioimmunoassay.
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ameliorated by treatment (a representative case is shown
in Figure 1B and 1C), but were unchanged in the 3 sub-
jects where CNS syndromes did not improve; this differ-
ence was statistically significant (p =0 . 0 2 9 ) .
Chronological changes in small signals did not corre-
spond with clinical outcome.
Discussion
First, from the largest prospective cohort of SLE patients
with or without active CNS syndrome, we found that
abnormal signals from conventional MRI alone did not
have sufficient predictive value to be practical for diag-
nosis of active CNS lupus, although they were associated
with active CNS lupus. Second, after assortment by size,
large signals (ø ≥ 10 mm) were found to occur only in
the CNS group while small signals (ø < 10 mm)
occurred in both the CNS and non-CNS groups with no
significant difference in frequency. Finally, we did find
that large signals were always reduced or resolved com-
pletely when CNS syndromes were ameliorated by treat-
ment but did not change when CNS syndromes did not
improve. In contrast, chronological changes in small sig-
nals were not related to clinical outcome. We believe
this is the first report analyzing predictive values of MRI
for diagnosis of active CNS lupus using a prospective
study of a large cohort of patients with and without NP
syndromes.
This study demonstrated that active CNS lupus was
not associated with elevated “SLEDAI scores without
CNS syndrome,” elevated anti-DNA antibody levels, or
decreased serum CH50 levels. The latter two are widely
recognized and clinically used as reliable laboratory tests
for estimating disease activity in patients with SLE
[20,21]. Our data support the common view that CNS
syndrome in SLE may occur independently from and in
Table 2 CNS syndromes of SLE patients (n = 191)
Manifestaions of CNS lupus* n % MRI positive†
Total 57 30 25 (44%)
Neurologic disorders 34 18 17 (50%)
Aseptic meningitis 5 3 1 (20%)
Cerebrovascular disease 1 1 1 (100%)
Demyelinating syndrome 5 3 4 (80%)
Headache‡ 5 3 4 (80%)
Movement disorder (chorea) 0 0
Myelopathy 2 1 1 (50%)
Seizures and seizure disorders 18 9 8 (44%)
Psychiatric disorders 36 19 16 (44%)
Acute confusional state 24 13 14 (58%)
Anxiety disorder 1 1 0 (0%)
Cognitive dysfunction§ 0 0
Mood disorders 9 5 2 (22%)
Psychosis 2 1 0 (0%)
* Based on American College of Rheumatology case definitions for neuropsychiatric ayndromes in SLE
†An MRI test was defined to be ‘positive’ when any abnormal intensity lesion was found.
‡Excluding tension headache (episodic tension-type headache).
§Excluding slight or mild cognitive dysfunction without significant clinical impairment as revealed by detailed neuropsychological tests.
SLE: systemic lupus erythematosus; CNS: central nervous system
Table 3 MRI as a diagnostic tool for CNS lupus in 191 patients with SLE
MRI positive MRI negative Relative risk
(95% CI)
p PPV NPV
CNS Group 25 (44%) 32 (56%) 1.7 (1.1 - 2.7) 0.016 0.424 0.758
Neurologic disorders 17 (50%) 17 (50%) 2.3 (1.3 - 4.1) 0.007 0.333 0.855
Psychiatric disorders 16 (44%) 20 (56%) 1.9 (1.1 - 3.4) 0.038 0.320 0.833
Non-CNS Group 34 (25%) 100 (75%) - - - -
*An MRI test was defined to be ‘positive’ when any abnormal intensity lesion was found.
†P values were determined by Fisher’s exact test and CNS group or its subgroup is compared with non-CNS group.
CI: Confidence Interval; PPV: positive predictive value; NPV: negative predictive value
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vement [22].
Although we observed abnormal signal intensities in
the brain MRIs of the CNS group more frequently than
in those of the non-CNS group, the PPV (42%) and the
NPV (76%) of MRI for detecting active CNS lupus indi-
cate that conventional MRI alone is insufficiently speci-
fic to serve as a diagnostic tool for active CNS lupus.
Active CNS lupus was diagnosed in less than half of the
patients with abnormal signal intensities in brain MRI,
even though normal MRI findings tended to be asso-
ciated with non-CNS lupus. We also categorized
patients by CNS manifestations indicating neurologic or
psychiatric disorders but did not find any better results.
In fact, MRI has been shown to be neither very sensitive
nor specific for the diagnosis of NPSLE, estimates of
sensitivity and specificity being in the 30 and 40%,
respectively [12]. We would like to point out that these
figures had been only estimates without solid evidence
until this study. Thus, the diagnosis of CNS syndrome
in SLE remains a difficult task requiring careful clinical
and laboratory assessment together with such evaluation
techniques as neuroimaging, electroencephalography
and cerebrospinal fluid tests [7,12].
While exploring the usefulness of conventional MRI,
we found that a large MRI signal is useful as a diag-
nostic and surrogate marker for CNS lupus. Large
abnormal MRI signals (ø ≥ 10 mm) were seen only in
the CNS group whereas small abnormal MRI signals (ø
< 10 mm) were seen in both groups with no significant
difference. In addition, chronological changes in large
signals always corresponded with clinical outcome
while those of small signals did not. This kind of
reversible large abnormal MRI signals has been
reported [4,12,15,23,24]. These large abnormal MRI
signals may include new infarcts, discrete gray matter
lesions, diffuse gray matter hyperintensities, and cere-
bral edema. These lesions, except for infarcts, are often
transitory and resolve completely with time and treat-
ment. The large abnormal MRI signals in the present
study included several types of features, such as
infarcts, diffuse gray matter hyperintensities, and wide-
spread grey and white matter T2 high signal changes
resembling those in acute disseminated encephalomye-
litis, accompanied by various CNS syndromes.
Although these large abnormal MRI signals were
attributed to different pathomechanisms, they exhib-
ited equal usefulness as a diagnostic and surrogate
marker. Therefore, our simple criterion (i.e., MRI sig-
nals with ø ≥ 10 mm) is applicable to daily clinical
practice without specialized knowledge of neuroima-
ging and regardless of the type of CNS syndromes
encountered. We believe this test will prove very bene-
ficial for clinical assessment of the condition.
B
C
A
Figure 1 Abnormal magnetic resonance imaging signals in
patients with systemic lupus erythematosus (SLE). (A) Typical
white-matter lesions in central nervous system (CNS) lupus in a
fluid-attenuated inversion-recovery (FLAIR) image of a 21-year-old
woman having a headache caused by benign intracranial
hypertension. Many foci of small-sized abnormal signals are visible
in the white-matter of the frontal and parietal lobes. This type of
abnormality was also observed in some of the SLE patients who
had no history of CNS syndrome. (B) FLAIR image of a 23-year-old
woman with demyelinating syndrome and acute confusional state,
showing multiple large hyperintensities involving both grey and
white matter (Case 3 in Table 5). (C) Remarkable resolution of the
clinical signs and imaging picture 3 months later, following high
dose glucocorticoid with intravenous cyclophosphamide therapy.
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tate focal lesions in the white matter have been reported
to be the most common brain MRI finding, tending to
be more frequently observed in the CNS than in the
non-CNS SLE patients in most published reports
[6,7,12,25,26]. These lesions appear anywhere in the
brain, including the brain stem, and are accompanied by
a variety of clinical presentation. These small punctuate
hyperintense T2-weighted focal lesions are frequently
nonspecific and interpreted as consistent with focal
ischemia, demyelination, vasculitis, microinfarcts, gliosis,
or other conditions. These small abnormal MRI signals
frequently correlate poorly with clinical manifestations,
and occur in patients without marked CNS signs and
symptoms. In addition, conventional MRI is not capable
of differentiating between older chronic and recent
acute lesions of this type.
Neuroimaging must be evaluated in the context of the
brain pathology of CNS lupus [4]. At this time, patholo-
gic studies have basically been limited to post mortem
studies of end stage SLE patients, which has seriously
limited understanding of the sequence of events in the
pathogenesis and progression of the disease [5]. More-
over, there have been few paired imaging-autopsy stu-
dies [4]. Despite the dramatic neurologic manifestations,
minimal histopathologic findings in CNS lupus are typi-
cal, with apparently normal findings or nonspecific
changes in the brain predominating. This general lack of
specific histopathology has complicated interpretation of
results found with nearly any imaging technique. For
example, the autopsy of one of the patients in the pre-
sent study who died from alveolar hemorrhage 5 years
after showing acute confusional state and several foci of
small-sized abnormal MRI signals in the white-matter
showed no remarkable findings in the brain.
One of the limitations of the present study is that its
subject number was insufficient for definitive conclu-
sions about significance of conventional MRI for diagno-
sis of CNS lupus, although it is appreciably larger than
previous studies dealing with NPSLE and MRI
[15,24,27]. Another potential weakness arises from the
fact that the MRI scans were not evaluated by multiple
Table 4 Large MRI signal as a diagnostic tool for CNS lupus in 191 patients with SLE
Large signal Negative or small signal Relative risk
(95% CI)
p PPV NPV
CNS group 7 (12%) 50 (88%) 3.7 (2.9 - 4.7) 0.0002 1.000 0.728
Neurologic Disorders 5 (15%) 29 (85%) 5.6 (4.0 - 7.8) 0.0003 1.000 0.822
Psychiatric Disorders 5 (14%) 31(86%) 5.3 (3.9 - 7.3) 0.0003 1.000 0.812
Non-CNS group 0 (0%) 134 (100%) - - - -
*Abnormal MRI signals were classified into large (ø ≥ 10 mm) or small abnormal MRI signals (ø < 10 mm).
†P values were determined by Fisher’s exact test and CNS group or its subgroup is compared with non-CNS group.
CI: Confidence Interval; PPV: positive predictive value; NPV: negative predictive value
Table 5 Characteristics of the CNS lupus patients with large abnormal MRI signals
Case Duration of
SLE (yrs)
SLEDAI SLEDAI
without
CNS
aPL* SLE-related CNS syndrome Treatment Clinical outcome
of CNS lupus
MRI
change
1 0 31 15 Positive Seizure disorder, Headache Steroids Improve Improve
2 0 11 3 Negative Acute confusional state Steroids + CPA Improve Improve
3 1 24 8 Negative Demyelinating syndrome, Acute
confusional state
Steroids + CPA Improve Improve
4 9 29 5 Positive Demyelinating syndrome, Seizure
disorder, Acute confusional state
Steroids + CPA Improve Improve
5 4 16 0 Negative Demyelinating syndrome, Acute
confusional state
Steroids + CPA No change No change
6 8 10 2 Negative Cerebrovascular disease Steroids + CPA +
anticoagulant
No change No change
7 5 22 6 Negative Acute confusional state Steroids + CPA No change Deteriorate
CNS: central nervous system; MRI: magnetic resonance imaging; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index;
aPL: antiphospholipid antibody; CPA: cyclophosphamide.
*aPL includes lupus anticoagulant, anti-cardiolipin antibodies, and anti-b2GPI antibodies.
†The case numbers given are not identifying numbers.
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nately, it has been shown that evaluation of these scans
is generally consistent among observers, so cranial MRI
may be considered to be a valid technique to assess dis-
ease progression or reversal [15]. Because we did not
include SLE patients who had CNS syndromes caused
by non-SLE pathologies, the value of MRI for diagnosis
of these conditions was not determined by this study.
Thus, it is not clear from this study whether CNS syn-
dromes caused by non-SLE pathologies can be differen-
tiated by MRI, including the large MRI abnormal
signals.
Conclusions
MRI alone does not have sufficient predictive value for
the diagnosis of active CNS lupus, although abnormal
MRI signals showed a significant association with CNS
syndrome. Importantly, a large MRI signal is a reliable
and practical diagnostic and surrogate marker for CNS
syndrome in SLE. The relatively small number of sub-
jects having large MRI signals in the study indicates the
need for further studies in larger numbers of patients to
validate the findings.
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